What is Theranova?
Theranova operates as a specialized medical device incubator, founded by Dr. Dan Burnett with a clear mandate to improve patient outcomes, expand healthcare access, and reduce systemic costs. The company distinguishes itself through a triple-aim framework that integrates the entire lifecycle of medical device development—from initial concept to market-ready solution—within a centralized, shared-services infrastructure. This operational model allows Theranova to maintain a lean, highly efficient development process, effectively mitigating the risks typically associated with early-stage medical technology ventures while targeting large, underserved markets.
How much funding has Theranova raised?
Theranova has raised a total of $826K across 2 funding rounds:
Debt
$350K
Debt
$476K
Debt (2020): $350K with participation from PPP
Debt (2021): $476K led by PPP
Key Investors in Theranova
PPP
Public-Private Partnership
What's next for Theranova?
With the recent influx of capital, Theranova is well-positioned to accelerate its pipeline of innovative medical solutions. The company's strategic roadmap likely involves scaling its incubator operations to support a broader portfolio of devices that align with its core mission of cost-effective healthcare delivery. As the firm moves forward, the focus will remain on navigating complex regulatory environments and optimizing its shared-services model to ensure that its technological advancements reach clinical settings with maximum efficiency. This major enterprise-level funding provides the necessary runway to sustain long-term research and development initiatives, further cementing Theranova's role as a pivotal player in the evolution of modern medical device engineering.
See full Theranova company page
